These outcomes strongly suggest that dose reduction of sulfonylureas is important when adding an SGLT-2 inhibitor to sulfonylurea treatment, and it is important to determine the efficacy of this measure in minimizing the risk of hypoglycemia. Here, SLC5A2 is linked to Hypoglycemia.